Immunotherapy for prostate cancer

Robert Jeffrey Karnes, Christopher M. Whelan, Eugene D Kwon

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to treat prostate cancer. Immune-based strategies to treat prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumor antigens that can be targeted, either by antibody or T cells, to promote prostate tumor cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumors. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of the T cell costimulatory pathway receptors can greatly facilitate tumorspecific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. Therefore, in this review we summarize recent advances pertaining to immunotherapeutic approaches to treat prostate cancer.

Original languageEnglish (US)
Pages (from-to)807-817
Number of pages11
JournalCurrent Pharmaceutical Design
Volume12
Issue number7
DOIs
StatePublished - Mar 2006

    Fingerprint

Keywords

  • Antigen-presenting cells (APCs)
  • Herceptin
  • Interleukin
  • Monoclonal Antibodies
  • Prostate specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this